Acromegaly – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Acromegaly – Pipeline Review, H1 2018’, provides an overview of the Acromegaly pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Acromegaly

– The report reviews pipeline therapeutics for Acromegaly by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Acromegaly therapeutics and enlists all their major and minor projects

– The report assesses Acromegaly therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Acromegaly

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Acromegaly

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aegis Therapeutics LLC

Amryt Pharma plc

Antisense Therapeutics Ltd

Aquestive Therapeutics

Chiasma Inc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Dauntless Pharmaceuticals Inc

DexTech Medical AB

Ionis Pharmaceuticals Inc

Italfarmaco SpA

leon-nanodrugs GmbH

Midatech Pharma Plc

Novartis AG

Peptron Inc

Silence Therapeutics Plc

Strongbridge Biopharma plc

Sun Pharmaceutical Industries Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acromegaly Overview

Acromegaly Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Acromegaly Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acromegaly Companies Involved in Therapeutics Development

Aegis Therapeutics LLC

Amryt Pharma plc

Antisense Therapeutics Ltd

Aquestive Therapeutics

Chiasma Inc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Dauntless Pharmaceuticals Inc

DexTech Medical AB

Ionis Pharmaceuticals Inc

Italfarmaco SpA

leon-nanodrugs GmbH

Midatech Pharma Plc

Novartis AG

Peptron Inc

Silence Therapeutics Plc

Strongbridge Biopharma plc

Sun Pharmaceutical Industries Ltd

Acromegaly Drug Profiles

Antisense Oligonucleotide to Inhibit Growth Hormone Receptor for Acromegaly Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-102 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atesidorsen sodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRN-00808 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-GHRLRx Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ITF-2984 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanreotide SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leon-03 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate long acting Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Somadex Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acromegaly Dormant Projects

Acromegaly Discontinued Products

Acromegaly Product Development Milestones

Featured News & Press Releases

Feb 28, 2018: ATL1103/atesidorsen Early Access Program - Update

Jan 30, 2018: FDA Grants Orphan Drug Designation to Dauntless Pharmaceuticals DP1038 for the Treatment of Acromegaly

Jan 09, 2018: Midatech receives confirmation that its Q-Octreotide (MTD201) first in-human EU study is approved

Jan 08, 2018: Chiasma Reports on Significant Progress Made During 2017

Dec 22, 2017: Antisense Therapeutics Executes Agreement to Implement ATL1103 / atesidorsen Early Access Program for Patients with Acromegaly

Oct 26, 2017: Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly

Oct 19, 2017: Clinical Data from Phase 1 PK/PD Study of Octreotide for Intranasal Delivery to be Presented at North American Neuroendocrine Tumor Society Symposium

Sep 27, 2017: Chiasma Announces First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide Capsules in Patients with Acromegaly

Sep 04, 2017: Midatech Submits MTD201 CTA Filing For First-in Human Study in Carcinoid Cancer and Acromegaly

Aug 10, 2017: Chiasma Reaches Agreement with FDA under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly

Jul 13, 2017: Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808

May 04, 2017: Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery

Mar 10, 2017: Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility

Feb 23, 2017: ATL1103 Update proposed International Nonproprietary Name for ATL1103

Feb 16, 2017: Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Acromegaly, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Acromegaly Pipeline by Aegis Therapeutics LLC, H1 2018

Acromegaly Pipeline by Amryt Pharma plc, H1 2018

Acromegaly Pipeline by Antisense Therapeutics Ltd, H1 2018

Acromegaly Pipeline by Aquestive Therapeutics, H1 2018

Acromegaly Pipeline by Chiasma Inc, H1 2018

Acromegaly Pipeline by Crinetics Pharmaceuticals Inc, H1 2018

Acromegaly Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Acromegaly Pipeline by Dauntless Pharmaceuticals Inc, H1 2018

Acromegaly Pipeline by DexTech Medical AB, H1 2018

Acromegaly Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Acromegaly Pipeline by Italfarmaco SpA, H1 2018

Acromegaly Pipeline by leon-nanodrugs GmbH, H1 2018

Acromegaly Pipeline by Midatech Pharma Plc, H1 2018

Acromegaly Pipeline by Novartis AG, H1 2018

Acromegaly Pipeline by Peptron Inc, H1 2018

Acromegaly Pipeline by Silence Therapeutics Plc, H1 2018

Acromegaly Pipeline by Strongbridge Biopharma plc, H1 2018

Acromegaly Pipeline by Sun Pharmaceutical Industries Ltd, H1 2018

Acromegaly Dormant Projects, H1 2018

Acromegaly Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Acromegaly, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports